Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 70

Single-center, first-in-human injection of ceAF for knee osteoarthritis

Official title: A Research Collaboration Project to Evaluate the Efficacy and Safety of Animal Early Embryo Extract ceAF in the Treatment of Patients With Knee Osteoarthritis

Run by Anhui HygeianCells BioMedical Co., Ltd. · NCT07902128 · Data updated 2026-11-12

This early-stage study tests a single knee injection of ceAF to see if it is safe and helps reduce pain and improve function in adults with knee osteoarthritis.

More Knee Arthritis, Osteoarthritis trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment26 (estimated)
SponsorAnhui HygeianCells BioMedical Co., Ltd.
Industry-sponsored
Locations1 site (Huangshan City, Anhui)
StatusRecruiting
StartedDecember 10, 2025
Main results expectedMarch 2027
Study endsNovember 30, 2027
Registry record updatedOctober 28, 2026
Trial IDNCT07902128 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-70 with radiographically confirmed knee osteoarthritis (Kellgren-Lawrence grade III or IV) and knee pain 4–7/10 who have had disease for at least 6 months and up to 10 years.

Probably not a fit

Patients with higher body mass index, significant comorbidities, or contraindications to intra-articular injections may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 1, open-label, dose-escalation study conducted at a single center to evaluate intra-articular ceAF in adults with knee osteoarthritis. Part 1 tests three dose levels (1.0, 1.5, and 2.0 mL) with 3-5 participants per level to establish safety and initial signals of efficacy. Part 2 administers the most favorable dose weekly for 2-3 injections to an additional 6-10 participants. Participants are followed for 12 weeks after the last injection, with safety monitoring and assessments of structural and patient-reported outcomes. The study uses imaging and clinical scales to track changes from baseline in knee structure and function.

Why it matters

Potential benefit: If successful, ceAF could provide pain relief and improved knee function with a cell-free approach for knee OA.

How similar studies have gone: Preclinical data and early investigator-initiated work suggest potential activity and safety for ceAF; this is among the first intra-articular knee OA studies of ceAF.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Participant (or legal representative) voluntarily agrees to participate and provides written informed consent.
2. Age 18-70 years, inclusive; male or female.
3. Definite diagnosis of knee osteoarthritis according to the 2010 diagnostic criteria of the Rheumatology Branch of the Chinese Medical Association.
4. Duration of knee osteoarthritis of 6 months or more and less than 10 years.
5. Knee pain VAS score of 4 or more and less than 8 in both knees, assessed at least 3 days after discontinuation of all analgesic medication.
6. Kellgren-Lawrence grade III or IV on X-ray of both knees.
7. Able to walk independently; participants requiring crutches, a walker or a wheelchair are not eligible.

Exclusion Criteria:

1. Allergy to one or more drugs, to eggs, or to two or more foods.
2. Body mass index greater than 30 kg/m2.
3. Uncontrolled or difficult-to-control cardiovascular, cerebrovascular, hepatic, renal, pulmonary, endocrine or other systemic disease.
4. History of malignant tumour.
5. Concomitant systemic or rheumatic arthritis chondropathy, chondrocalcinosis, haemochromatosis, infectious arthropathy, avascular necrosis of the femoral head, Paget's disease, haemophilic arthropathy, Charcot arthropathy, pigmented villonodular synovitis or synovial chondromatosis.
6. Relatively severe systemic infection, or local knee joint infection (including skin and intra-articular infection), within 3 months before the start of the study.
7. Relatively severe lower limb disease that may interfere with knee assessment, such as fibromyalgia, significant low back pain or lumbar disc herniation.
8. Coagulation disorder.
9. Knee arthroscopic surgery, or other open surgery involving the knee, within 6 months before the start of the study.
10. Intra-articular injection for knee osteoarthritis within 6 months before the start of the study, including but not limited to hyaluronic acid, corticosteroids, platelet-rich plasma and bone morphogenetic protein.
11. Glucosamine and/or chondroitin sulfate treatment within 4 weeks before the start of the study.

Where it's running

  • Huangshan People's Hospital
    Huangshan City, Anhui, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.